文献速递胃肠动力与功能性疾病

比较腹泻型肠易激综合征治疗的成本与结局:成本效益分析

Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-10-01

该研究构建决策分析模型,评估指南推荐药物、FDA新近批准药物、补充剂、低FODMAP饮食及认知行为疗法治疗腹泻型肠易激综合征的成本效益。从保险方视角,处方药显著贵于非适应症治疗、低FODMAP或认知行为疗法,偏好由药品均价驱动且不受健康获益影响;从患者视角,处方药和神经调节剂因减少误工而更受偏好,但自付费用在低支付意愿阈值下比健康结局更重要。

要点

  • 保险方偏好由处方药平均批发价驱动,在高达15万美元/QALY的支付意愿范围内不受健康获益影响。
  • 患者视角下处方药和神经调节剂因减少误工而更受偏好,低支付意愿阈值时自付费用比健康结局更重要。
  • 患者与保险方的成本驱动因素不同,可解释实践中双方治疗偏好的错位。

核心结论

  • 成本是患者和保险方衡量IBS治疗价值的关键决定因素,但驱动双方治疗偏好的成本因素不同,这种差异可解释实践中患者与保险方治疗偏好的错位。

研究设计与样本

  • 构建决策分析模型,评估指南推荐药物、FDA新近批准药物、补充剂、低FODMAP饮食和认知行为疗法治疗腹泻型肠易激综合征的成本效益。
  • 结局与成本来自临床试验的系统评价和国家数据库,健康获益以质量调整生命年(QALY)表示。

主要发现

  • 从保险方视角,适应症内处方药(利福昔明、艾沙度林、阿洛司琼)显著贵于非适应症治疗、低FODMAP饮食或认知行为疗法。
  • 保险方治疗偏好由处方药平均批发价驱动,在高达150,000美元/QALY的支付意愿范围内敏感性分析中不受健康获益影响。
  • 从患者视角,处方药和神经调节剂因有效治疗减少IBS导致的误工损失而显得更可取,同时考虑低FODMAP食物的自付费用和参加认知行为疗法预约的自付费用。
  • 患者视角的成本效益分析中,比较健康结局对治疗偏好的影响取决于患者对额外健康获益的支付意愿阈值,但在较低支付意愿阈值下健康结局不如自付费用重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Irritable bowel syndrome (IBS) is one of the most expensive gastroenterological conditions and is an ideal target for developing a value-based care model. We assessed the comparative cost-benefit of treatments for IBS with diarrhea (IBS-D), the most common IBS subtype from insurer and patient perspectives. METHODS: We constructed a decision analytic model assessing trade-offs among guideline-recommended and recently FDA-approved drugs, supplements, low FODMAP diet, cognitive behavioral therapy (CBT). Outcomes and costs were derived from systematic reviews of clinical trials and national databases. Health-gains were represented using quality-adjusted life years (QALY). RESULTS: From an insurer perspective, on-label prescription drugs (rifaximin, eluxadoline, alosetron) were significantly more expensive than off-label treatments, low FODMAP, or CBT. Insurer treatment preferences were driven by average wholesale prescription drug prices and were not affected by health gains in sensitivity analysis within standard willingness-to-pay ranges up to $150,000/QALY-gained. From a patient perspective, prescription drug therapies and neuromodulators appeared preferable due to a reduction in lost wages due to IBS with effective therapy, and also considering out-of-pocket costs of low FODMAP food and out-of-pocket costs to attend CBT appointments. Comparative health outcomes exerted influence on treatment preferences from a patient perspective in cost-benefit analysis depending on a patients' willingness-to-pay threshold for additional health-gains, but health outcomes were less important than out-of-pocket costs at lower willingness-to-pay thresholds. CONCLUSIONS: Costs are critical determinants of IBS treatment value to patients and insurers, but different costs drive patient and insurer treatment preferences. Divergent cost drivers appear to explain misalignment between patient and insurer IBS treatment preferences in practice.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shah ED, Salwen-Deremer JK, Gibson PR, et al. Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. Clin Gastroenterol Hepatol. 2020. PMID: 33010413. doi:10.1016/j.cgh.2020.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。